More specifically, we have shown that a well-established anti-melanoma chemotherapeutic, melphalan fails to induce sufficiently high immunogenicity in vivo, because it is not able to induce the relevant threshold levels of reactive oxygen species (ROS)-based ER stress required for ecto-CRT induction (Figure 1) [1]. This evidence concerns the gene CALR and melanoma.